Ellipses Pharma licences SRB22 from SunRock Biopharma
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Evotec signs contracts with Almirall and Sernova
Hamburg-based CRO Evotec SE has inked a drug development partnership with Spanish Almirall SA in dematology.
Avantium gets EU grant
Avantium NV will get a €3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.
Enzymaster raises $45m in Series C round
Biocatalysis expert Enzymaster (Germany, China, Singapore) has cashed in $45m to expand its production capacity of engineered biosynthetic enzymes.
EU starts consultation on novel plant breeding methods
The EU Commission has launched its final consultation on the deregulation of new breeding techniques in agriculture.
Evotec and BMS intensify R&D on protein degraders
Hamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional eight years.
Bristol Myers Squibb brings in a huge library of E3 ligase modulators. Under the terms of the agreement, both parties will leverage all of Evotecs appropriate platforms as well as AI/ML-based drug discovery.
Under the new agreement, Evotec cashes in an upfront payment of $200m and is eglible to obtain up to $5bn in milestone payments and tiered royalties on product sales.
New Laser Fluorescence Technique can deliver unique information in drug discovery
The optically pumped semiconductor laser (OPSL) is an ideal light source for structured illumination microscopy (SIM), a laser fluorescence technique that can deliver unique information in drug discovery.
Replacing beef with cellular protein halves deforestation
Replacing 20% of global beef consumption with fermentation-derived microbial protein by 2050 could halve annual deforestation and associated carbon dioxide emissions.
Hot of the press: BIOTECH Insight Newsletter
Deutsche Börse report key growth figures of the German biotech sector in 2021 in BIOTECH Insight, its new online information service published in collaboration with BIOCOM AG.
Engimmune Therapeutics raises CHF15.5m in seed financing
Cancer specialist Engimmune Therapeutics has raised CHF15.5m in a seed financing to expand its pipeline of T-cell receptor therapeutics.